Clinical Research Directory

Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.

Sponsor: Novartis Pharmaceuticals

Summary

The goal of this study is to understand the long-term treatment strategies in children and adolescents diagnosed with ERA or JPsA who received secukinumab and achieved inactive disease and to evaluate the long-term treatment effectiveness of secukinumab in the ERA or JPsA patients in the postauthorization setting.

Official title: Long-term Treatment Strategies and Effectiveness of Secukinumab in Juvenile Idiopathic Arthritis Patients of Psoriatic and Enthesitis-related Arthritis Categories: Secondary Use of Data and Primary Data Collection From the German BIKER Registry

Key Details

Conditions

Interventions